Company profile: Santhera Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of pharmaceutical products for mitochondrial and neuromuscular diseases; develops and markets therapies for areas of high unmet medical need, including many orphan and niche indications with no current therapy, such as Vamorolone for Duchenne muscular dystrophy targeting inflammation and dystrophic cardiomyopathy.
Products and services
- Vamorolone: A specialty pharmaceutical for Duchenne muscular dystrophy that targets inflammation and dystrophic cardiomyopathy, engineered to address high unmet medical need in neuromuscular conditions
- Innovative Pharmaceutical Development: Orphan-focused programs that architect and advance new therapies for mitochondrial and neuromuscular diseases, specifically targeting high unmet medical need across indications lacking current treatment options
- Specialty Pharmaceutical Marketing: Niche-focused commercialization that delivers and markets innovative pharmaceutical products for mitochondrial and neuromuscular diseases to address areas with no current therapy
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Santhera Pharmaceuticals
Xanodyne
HQ: United States
Website
- Description: Provider of integrated specialty pharmaceutical products, developing and commercializing offerings in women's healthcare and pain management in the United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xanodyne company profile →
Contera Pharma
HQ: Denmark
Website
- Description: Provider of drug discovery and development focused on innovative treatments for movement disorders, collaborating with expert individuals and organizations. Lead program JM-010 combines immediate-release buspirone and extended-release zolmitriptan to treat dyskinesia associated with dopamine replacement therapies in Parkinson’s disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Contera Pharma company profile →
CanniMed
HQ: Canada
Website
- Description: Provider of standardized, pharmaceutical-grade medical cannabis in Canada, operating as a plant biopharmaceutical company under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CanniMed company profile →
Knopp Biosciences
HQ: United States
Website
- Description: Provider of clinical-stage small-molecule treatments, including dexpramipexole for eosinophilic asthma and a Kv7 platform for epilepsy and other hyperexcitability disorders; engaged in drug discovery and development for neurological disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Knopp Biosciences company profile →
U.S. WorldMeds
HQ: United States
Website
- Description: Provider of specialty pharmaceutical therapies: IWILFIN, an oral maintenance therapy reducing relapse risk in high-risk neuroblastoma after prior treatment response; ZIMHI, a high-dose naloxone injection for emergency treatment of opioid overdose, effective against powerful synthetic opioids like fentanyl; and LUCEMYRA, an oral drug that mitigates opioid withdrawal to facilitate abrupt discontinuation in adults.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full U.S. WorldMeds company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Santhera Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Santhera Pharmaceuticals
2.2 - Growth funds investing in similar companies to Santhera Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Santhera Pharmaceuticals
4.2 - Public trading comparable groups for Santhera Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →